Table 2.
Ongoing trials in Alzheimer’s disease related to identified candidate drugs.
| Drug | Phase and location | Study description | Status | Trial completion date | Clinical trial number |
|---|---|---|---|---|---|
| Acitretin | II Germany | 28 days of 30 mg acitretin treatment in patients with mild to moderate Alzheimer’s Disease. The primary objective is to measure the change in APPsα levels in CSF | Recruiting | April 2011 | NCT01078168 |
| Exenatide | II USA | Exenatide in early AD or MCI, with planned follow up using sum of boxes and ADAS-COG for 36 months following treatment. MRI and CSF biomarkers as secondary measures | Recruiting | Dec 2015 | NCT01255163 |
| Liraglutide | II Denmark | 26 weeks liraglutide (IV) or placebo in mild AD. Primary outcome is amyloid load by PIB PET imaging | Completed, awaiting publication | June 2013 | NCT01469351 |
| Nilvadipine | III Europe | 18 month placebo controlled RCT in 500 people with AD across 18 European sites funded by the European Union | Finalizing protocol | tbc | tbc |